Drug Trial Radar · NCT07364422
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
Feb 27, 2026
Primary completion
Feb 28, 2026
Study completion Feb 28, 2029
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
Conditions
- Gastric Cancer (GC)
Interventions
JPI-547Drug
The dose levels will be escalated following a 3+3 dose escalation scheme.
Irinotecan (drug)Drug
The dose levels will be escalated following a 3+3 dose escalation scheme.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 1b: dose-limiting toxicity rateTime frame: The dose-limiting toxicity evaluation window is 28 days from C1D1.
- phase 2: Overall Response Rate (ORR) according to RECIST v1.1Time frame: At 6-week intervals through study completion, an average of 3 years.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.